An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release financial and operational results for the second quarter of 2023 on August 3, 2023. The management team will host a conference call/webcast at 8:30 am ET to review the results and provide a general business update.
Positive
None.
Negative
None.
EDMONTON, Alberta--(BUSINESS WIRE)--
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (888) 645-4404 / (862) 298-0702 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
What is the ticker symbol of the company mentioned in the press release?
The ticker symbol is AUPH for Aurinia Pharmaceuticals Inc.
When will the financial and operational results for the second quarter of 2023 be released?
The results will be released on Thursday, August 3, 2023, before markets open.
How can interested participants access the conference call/webcast?
Interested participants can dial (888) 645-4404 / (862) 298-0702 (Toll-free U.S. & Canada) or access the audio webcast through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com.
Will a replay of the webcast be available?
Yes, a replay of the webcast will be available on Aurinia’s website.
